HPV16 antibodies as risk factors for oropharyngeal cancer and their association with tumor HPV and smoking status

Karen Anderson, Kristina R. Dahlstrom, Julia N. Cheng, Rizwan Alam, Guojun Li, Qingyi Wei, Neil D. Gross, Diego Chowell, Marshall Posner, Erich M. Sturgis

    Research output: Contribution to journalArticle

    31 Citations (Scopus)

    Abstract

    Background Antibodies (Abs) to the HPV16 proteome increase risk for HPV-associated OPC (HPVOPC). The goal of this study was to investigate the association of a panel of HPV16 Abs with risk for OPC as well as the association of these Abs with tumor HPV and smoking status among patients with OPC. Methods IgG Abs to the HPV16 antigens E1, E2, E4, E5, E6, E7, L1, L2 were quantified using a programmable ELISA assay. Sera were obtained from 258 OPC patients at diagnosis and 250 healthy controls. HPV16 tumor status was measured by PCR for 137 cases. Multivariable logistic regression was used to calculate odds ratios for the association of HPV16 Abs with risk for OPC. Results HPV16 E1, E2, E4, E5, E6, E7 and L1-specific IgG levels were elevated in OPC patients compared to healthy controls (p < 0.05). After multivariable adjustment, Ab positivity for NE2, CE2, E6, and/or E7 was associated with OPC risk (OR [95% CI], 249.1 [99.3-624.9]). Among patients with OPC, Ab positivity for these antigens was associated with tumor HPV status, especially among never or light smokers (OR [95% CI], 6.5 [2.1-20.1] and OR [95% CI], 17.5 [4.0-77.2], respectively). Conclusions Antibodies to HPV16 proteins are associated with increased risk for HPVOPC. Among patients with OPC, HPV16 Abs are associated with tumor HPV status, in particular among HPV positive patients with no or little smoking history.

    Original languageEnglish (US)
    Pages (from-to)662-667
    Number of pages6
    JournalOral Oncology
    Volume51
    Issue number7
    DOIs
    StatePublished - Jul 1 2015

    Fingerprint

    Oropharyngeal Neoplasms
    Smoking
    Antibodies
    Neoplasms
    Immunoglobulin G
    Neoplasm Antibodies
    Social Adjustment
    Proteome
    Logistic Models
    History
    Enzyme-Linked Immunosorbent Assay
    Odds Ratio
    Antigens
    Polymerase Chain Reaction
    Serum

    Keywords

    • Antibodies
    • Biomarker
    • Head and neck cancer
    • HPV
    • Oropharyngeal cancer
    • Serology

    ASJC Scopus subject areas

    • Oncology
    • Oral Surgery
    • Cancer Research

    Cite this

    HPV16 antibodies as risk factors for oropharyngeal cancer and their association with tumor HPV and smoking status. / Anderson, Karen; Dahlstrom, Kristina R.; Cheng, Julia N.; Alam, Rizwan; Li, Guojun; Wei, Qingyi; Gross, Neil D.; Chowell, Diego; Posner, Marshall; Sturgis, Erich M.

    In: Oral Oncology, Vol. 51, No. 7, 01.07.2015, p. 662-667.

    Research output: Contribution to journalArticle

    Anderson, K, Dahlstrom, KR, Cheng, JN, Alam, R, Li, G, Wei, Q, Gross, ND, Chowell, D, Posner, M & Sturgis, EM 2015, 'HPV16 antibodies as risk factors for oropharyngeal cancer and their association with tumor HPV and smoking status' Oral Oncology, vol. 51, no. 7, pp. 662-667. https://doi.org/10.1016/j.oraloncology.2015.04.011
    Anderson, Karen ; Dahlstrom, Kristina R. ; Cheng, Julia N. ; Alam, Rizwan ; Li, Guojun ; Wei, Qingyi ; Gross, Neil D. ; Chowell, Diego ; Posner, Marshall ; Sturgis, Erich M. / HPV16 antibodies as risk factors for oropharyngeal cancer and their association with tumor HPV and smoking status. In: Oral Oncology. 2015 ; Vol. 51, No. 7. pp. 662-667.
    @article{670955aea7e74eff815a3d4d8cd570cf,
    title = "HPV16 antibodies as risk factors for oropharyngeal cancer and their association with tumor HPV and smoking status",
    abstract = "Background Antibodies (Abs) to the HPV16 proteome increase risk for HPV-associated OPC (HPVOPC). The goal of this study was to investigate the association of a panel of HPV16 Abs with risk for OPC as well as the association of these Abs with tumor HPV and smoking status among patients with OPC. Methods IgG Abs to the HPV16 antigens E1, E2, E4, E5, E6, E7, L1, L2 were quantified using a programmable ELISA assay. Sera were obtained from 258 OPC patients at diagnosis and 250 healthy controls. HPV16 tumor status was measured by PCR for 137 cases. Multivariable logistic regression was used to calculate odds ratios for the association of HPV16 Abs with risk for OPC. Results HPV16 E1, E2, E4, E5, E6, E7 and L1-specific IgG levels were elevated in OPC patients compared to healthy controls (p < 0.05). After multivariable adjustment, Ab positivity for NE2, CE2, E6, and/or E7 was associated with OPC risk (OR [95{\%} CI], 249.1 [99.3-624.9]). Among patients with OPC, Ab positivity for these antigens was associated with tumor HPV status, especially among never or light smokers (OR [95{\%} CI], 6.5 [2.1-20.1] and OR [95{\%} CI], 17.5 [4.0-77.2], respectively). Conclusions Antibodies to HPV16 proteins are associated with increased risk for HPVOPC. Among patients with OPC, HPV16 Abs are associated with tumor HPV status, in particular among HPV positive patients with no or little smoking history.",
    keywords = "Antibodies, Biomarker, Head and neck cancer, HPV, Oropharyngeal cancer, Serology",
    author = "Karen Anderson and Dahlstrom, {Kristina R.} and Cheng, {Julia N.} and Rizwan Alam and Guojun Li and Qingyi Wei and Gross, {Neil D.} and Diego Chowell and Marshall Posner and Sturgis, {Erich M.}",
    year = "2015",
    month = "7",
    day = "1",
    doi = "10.1016/j.oraloncology.2015.04.011",
    language = "English (US)",
    volume = "51",
    pages = "662--667",
    journal = "Oral Oncology",
    issn = "1368-8375",
    publisher = "Elsevier Limited",
    number = "7",

    }

    TY - JOUR

    T1 - HPV16 antibodies as risk factors for oropharyngeal cancer and their association with tumor HPV and smoking status

    AU - Anderson, Karen

    AU - Dahlstrom, Kristina R.

    AU - Cheng, Julia N.

    AU - Alam, Rizwan

    AU - Li, Guojun

    AU - Wei, Qingyi

    AU - Gross, Neil D.

    AU - Chowell, Diego

    AU - Posner, Marshall

    AU - Sturgis, Erich M.

    PY - 2015/7/1

    Y1 - 2015/7/1

    N2 - Background Antibodies (Abs) to the HPV16 proteome increase risk for HPV-associated OPC (HPVOPC). The goal of this study was to investigate the association of a panel of HPV16 Abs with risk for OPC as well as the association of these Abs with tumor HPV and smoking status among patients with OPC. Methods IgG Abs to the HPV16 antigens E1, E2, E4, E5, E6, E7, L1, L2 were quantified using a programmable ELISA assay. Sera were obtained from 258 OPC patients at diagnosis and 250 healthy controls. HPV16 tumor status was measured by PCR for 137 cases. Multivariable logistic regression was used to calculate odds ratios for the association of HPV16 Abs with risk for OPC. Results HPV16 E1, E2, E4, E5, E6, E7 and L1-specific IgG levels were elevated in OPC patients compared to healthy controls (p < 0.05). After multivariable adjustment, Ab positivity for NE2, CE2, E6, and/or E7 was associated with OPC risk (OR [95% CI], 249.1 [99.3-624.9]). Among patients with OPC, Ab positivity for these antigens was associated with tumor HPV status, especially among never or light smokers (OR [95% CI], 6.5 [2.1-20.1] and OR [95% CI], 17.5 [4.0-77.2], respectively). Conclusions Antibodies to HPV16 proteins are associated with increased risk for HPVOPC. Among patients with OPC, HPV16 Abs are associated with tumor HPV status, in particular among HPV positive patients with no or little smoking history.

    AB - Background Antibodies (Abs) to the HPV16 proteome increase risk for HPV-associated OPC (HPVOPC). The goal of this study was to investigate the association of a panel of HPV16 Abs with risk for OPC as well as the association of these Abs with tumor HPV and smoking status among patients with OPC. Methods IgG Abs to the HPV16 antigens E1, E2, E4, E5, E6, E7, L1, L2 were quantified using a programmable ELISA assay. Sera were obtained from 258 OPC patients at diagnosis and 250 healthy controls. HPV16 tumor status was measured by PCR for 137 cases. Multivariable logistic regression was used to calculate odds ratios for the association of HPV16 Abs with risk for OPC. Results HPV16 E1, E2, E4, E5, E6, E7 and L1-specific IgG levels were elevated in OPC patients compared to healthy controls (p < 0.05). After multivariable adjustment, Ab positivity for NE2, CE2, E6, and/or E7 was associated with OPC risk (OR [95% CI], 249.1 [99.3-624.9]). Among patients with OPC, Ab positivity for these antigens was associated with tumor HPV status, especially among never or light smokers (OR [95% CI], 6.5 [2.1-20.1] and OR [95% CI], 17.5 [4.0-77.2], respectively). Conclusions Antibodies to HPV16 proteins are associated with increased risk for HPVOPC. Among patients with OPC, HPV16 Abs are associated with tumor HPV status, in particular among HPV positive patients with no or little smoking history.

    KW - Antibodies

    KW - Biomarker

    KW - Head and neck cancer

    KW - HPV

    KW - Oropharyngeal cancer

    KW - Serology

    UR - http://www.scopus.com/inward/record.url?scp=84930634108&partnerID=8YFLogxK

    UR - http://www.scopus.com/inward/citedby.url?scp=84930634108&partnerID=8YFLogxK

    U2 - 10.1016/j.oraloncology.2015.04.011

    DO - 10.1016/j.oraloncology.2015.04.011

    M3 - Article

    VL - 51

    SP - 662

    EP - 667

    JO - Oral Oncology

    JF - Oral Oncology

    SN - 1368-8375

    IS - 7

    ER -